Ser531
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Ser531 - BCLAF1 (human)

Site Information
KSTFREEsPLRIKMI    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: BCLAF1 (mouse): S529, BCLAF1 (rat): S531, BCLAF1 iso4 (human): S358, BCLAF1 iso3 (rat): S672, BCLAF1 iso3 (human): S529
Blast this site against: NCBI  SwissProt  PDB 
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (2, 4, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48), multiple reaction monitoring (MRM) (42)
Disease tissue studied: cervical cancer (15, 16), cervical adenocarcinoma (15, 16), leukemia (4), T cell leukemia (4), hepatocellular carcinoma, surrounding tissue (14), lung cancer (9), prostate cancer (28, 29)
Relevant cell line - cell type - tissue: 293 (epithelial) (35, 36, 37, 38, 42), 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] (11), 293 (epithelial) [AT1 (human), transfection] (10), 293T (epithelial) (45), A431 (epithelial) (48), A498 (renal) (13), CL1-0 (pulmonary) (9), CL1-1 (pulmonary) (9), CL1-2 (pulmonary) (9), CL1-5 (pulmonary) (9), GM00130 (B lymphocyte) (12), HCT116 (intestinal) (30), HeLa (cervical) (2, 5, 8, 30, 32, 33, 34, 39, 40, 41), HeLa S3 (cervical) (15, 16), hepatocyte-liver (14), HepG2 (hepatic) (19, 20, 22, 24, 27), HT-29 (intestinal) (46), HUES-7 ('stem, embryonic') (25), Jurkat (T lymphocyte) (31, 47), K562 (erythroid) (2, 44), Kit225 (T lymphocyte) (4), LNCaP (prostate cell) (28, 29), MKN-45 (gastric) (43), NCI-H2228 (pulmonary) (21, 23), NCI-H3255 (pulmonary) (17, 18, 26), NCI-H460 (pulmonary) (30)

Controlled by
Putative upstream kinases: GSK3B (human) (42)
Treatments: hesperadin (8), lithium (42), MG132 (8), nocodazole (8, 15)



References

1

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

2

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

3

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

4

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

5

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

6

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

7

Phanstiel DH, et al. (2011) Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nat Methods 8, 821-7
21983960   Curated Info

8

Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12
22067460   Curated Info

9

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

10

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

11

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

12

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

13

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

14

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

15

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

16

Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63
19691289   Curated Info

17

(2009) CST Curation Set: 7415; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H3255(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

18

(2009) CST Curation Set: 7416; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H3255(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

19

(2009) CST Curation Set: 7401; Year: 2009; SILAC: N; Biosample/Treatment: HepG2(cell line)/untreated; Disease: hepatocellular carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(K/R)XX(s/t)(phosphorylation)
Curated Info

20

(2009) CST Curation Set: 7402; Year: 2009; SILAC: N; Biosample/Treatment: HepG2(cell line)/untreated; Disease: hepatocellular carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(K/R)XX(s/t)(phosphorylation)
Curated Info

21

(2009) CST Curation Set: 7404; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H2228(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(K/R)XX(s/t)(phosphorylation)
Curated Info

22

(2009) CST Curation Set: 7408; Year: 2009; SILAC: N; Biosample/Treatment: HepG2(cell line)/untreated; Disease: hepatocellular carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

23

(2009) CST Curation Set: 7409; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H2228(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

24

(2009) CST Curation Set: 7407; Year: 2009; SILAC: N; Biosample/Treatment: HepG2(cell line)/untreated; Disease: hepatocellular carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

25

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

26

(2009) CST Curation Set: 7322; Year: 2009; SILAC: N; Biosample/Treatment: NCI-H3255(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

27

(2009) CST Curation Set: 7319; Year: 2009; SILAC: N; Biosample/Treatment: HepG2(cell line)/untreated; Disease: hepatocellular carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

28

(2009) CST Curation Set: 7231; Year: 2009; SILAC: N; Biosample/Treatment: LNCaP(cell line)/untreated; Disease: prostate cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

29

(2009) CST Curation Set: 7232; Year: 2009; SILAC: N; Biosample/Treatment: LNCaP(cell line)/PDBu; Disease: prostate cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

30

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

31

(2009) CST Curation Set: 6541; Year: 2009; SILAC: N; Biosample/Treatment: Jurkat(cell line)/untreated; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

32

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

33

(2009) CST Curation Set: 6249; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/UV; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

34

(2009) CST Curation Set: 6244; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/EGF; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

35

(2009) CST Curation Set: 6062; Year: 2009; SILAC: N; Biosample/Treatment: 293(cell line)/Insulin; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

36

(2009) CST Curation Set: 6061; Year: 2009; SILAC: N; Biosample/Treatment: 293(cell line)/rapamycin; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

37

(2009) CST Curation Set: 6060; Year: 2009; SILAC: N; Biosample/Treatment: 293(cell line)/Torin; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

38

(2009) CST Curation Set: 6059; Year: 2009; SILAC: N; Biosample/Treatment: 293(cell line)/control; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

39

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

40

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

41

Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6
18187866   Curated Info

42

Linding R, et al. (2007) Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415-26
17570479   Curated Info

43

(2007) CST Curation Set: 2893; Year: 2007; SILAC: N; Biosample/Treatment: MKN-45(cell line)/serum starved; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

44

(2007) CST Curation Set: 2629; Year: 2007; SILAC: N; Biosample/Treatment: K562(cell line)/normal; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

45

Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204
17287340   Curated Info

46

Kim JE, Tannenbaum SR, White FM (2005) Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 4, 1339-46
16083285   Curated Info

47

Zheng H, Hu P, Quinn DF, Wang YK (2005) Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol Cell Proteomics 4, 721-30
15659558   Curated Info

48

MS This site is one of 509 sites observed by D. Stover et al using MS/FTMS of peptides from lysates of A431 cells grown either in vitro or as xenografts in BALB/c nu/nu mice. These sites were previously unpublished until now (July 27 2006). 66 sites were previously published in: Stover DR, et al. Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts Clin Proteomics 2004 Mar 01; 1(1): 69-80.
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.